GW5074

Bezeichnung:GW5074

CAS-Nr220904-83-6

Englisch Name:GW5074

CBNumberCB0130215

SummenformelC15H8Br2INO2

Molgewicht520.94

MOL-Datei220904-83-6.mol

GW5074 physikalisch-chemischer Eigenschaften

Siedepunkt	561.4±50.0 °C(Predicted)
Dichte	2.248±0.06 g/cm3(Predicted)
storage temp.	room temp
Löslichkeit	DMSO: soluble
Aggregatzustand	solid
pka	5.86±0.25(Predicted)
Farbe	yellow to orange-brown
Stabilität	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey	LMXYVLFTZRPNRV-XCVCLJGOSA-N
CAS Datenbank	220904-83-6

Sicherheit

WGK Germany	3
HS Code	2933790090

Gefahreninformationscode (GHS)

GW5074 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
GW-5074 (220904-83-6) is a potent inhibitor of cRAF1 kinase (IC50 = 9 nM). Displays 100-fold selectivity for cRAF1 over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm. GW-5074 displays neuroprotective effects in vivo via a mechanism that is independent of MEK, ERK, and Akt signaling. Cell permeable.
Verwenden
GW5074 has been used as a specific inhibitor of cRaf1 in C2 murine skeletal myoblasts, HT-29 colorectal adenocarcinoma cell line and neutrophils.
Biologische Aktivität
Potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC 50 = 9 nM). Displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm.
Biochem/physiol Actions
GW5074 is a cRaf1 kinase inhibitor, which is placed immediately downstream of Ras in the Motogen activated protein kinase (MAPK) signaling pathway. It elicits protection in GW5074 prevents degeneration in Huntington′s disease and also have therapeutic potential in treating neurodegenerative disorders. GW5074 in combination with anti-inflammatory drug, dexamethasone, attenuates sidestream smoke-induced airway inflammation.
Lager
Desiccate at -20°C
Einzelnachweise
1) Chang et al. (2005), Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK pathways; Cell Signal., 217 299 2) Huang et al. (2006), Fibroblast growth factor-2 suppresses oridonin-induced L929 apoptosis through extracellular signal-regulated kinase-dependent and phosphatidylinositol 3-kinase-independent pathway; J. Pharmacol. Sci., 102 305 3) Lackey et al. (2000), The discovery of potent cRaf1 kinase inhibitors; Bioorg. Med. Chem. Lett., 10 223 4) Chen et al. (2004), Bradykinin B2 receptor mediates NF-kappaB activation and cyclooxygenase-2 expression via the Ras/Raf-1/ERK pathway in human airway epithelial cells; J. Immunol., 173 5219

GW5074 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy